Abstract
Coadministration of statin and fenofibrate monotherapies is frequently used to treat patients with dyslipidemia; however, a fixed-dose combination (FDC) tablet is not currently marketed. This study evaluates a new FDC tablet of atorvastatin 40 mg and fenofibrate 100 mg. This was a 12-week, multicenter, double-blind, randomized, parallel-group Phase IIb study. Adults with dyslipidemia (non-HDL-C >130 mg/dL and triglycerides [TG] > or =150 but < or =500 mg/dL) were randomly assigned in a 1:1:1 ratio to receive the FDC, atorvastatin 40 mg, or fenofibrate 145 mg for 12 weeks. Study medication was taken once daily in the evening, without regard to meals. Patients attended follow-up visits after 4, 8, and 12 weeks of the double-blind treatment. The primary efficacy end points were the mean percentage changes from baseline to the final visit (week 12) in non-HDL-C, HDL-C, and TG. Secondary variables were LDL-C, VLDL-C particle concentration, total cholesterol, apolipoprotein B, lipoprotein (a), high-sensitivity C-reactive protein, fibrinogen, homocysteine, creatinine, myeloperoxidase, and lipoprotein-associated phospholipase A2. Tolerability was assessed by adverse events, laboratory parameters, vital signs, physical examinations, and...Continue Reading
References
May 18, 2001·The American Journal of Cardiology·H N Ginsberg
Jun 28, 2002·Diabetes Care·Vasilios G AthyrosAthanasios G Kontopoulos
Sep 25, 2003·Biochemical Society Transactions·C J Packard
May 17, 2005·Journal of the American College of Cardiology·Kwang Kon KohEak Kyun Shin
Nov 18, 2005·The American Journal of Cardiology·Michael H Davidson
Dec 24, 2005·Expert Opinion on Drug Safety·Michael H Davidson
Jun 27, 2006·Clinical Cardiology·Michael H DavidsonUNKNOWN TRIMS Investigators
Mar 21, 2007·The American Journal of Cardiology·Michael H DavidsonTerry A Jacobson
Nov 11, 2008·Atherosclerosis·Peter H JonesJames C Stolzenbach
Dec 17, 2008·American Heart Journal·Syed M MohiuddinJames C Stolzenbach
Feb 7, 2009·The American Journal of Cardiology·Anne C GoldbergJames C Stolzenbach
Citations
Jan 18, 2013·Clinical and Experimental Pharmacology & Physiology·Qiang GengWenqing Liang
Sep 29, 2011·Drugs·Kate McKeage, Gillian M Keating
Dec 15, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Amirhossein SahebkarUNKNOWN Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
Jul 31, 2012·The American Journal of Cardiology·Jinrui GuoYingjie Qin
Aug 21, 2012·European Journal of Internal Medicine·Alexander ConstantinidesRobin P F Dullaart
Aug 2, 2011·Mayo Clinic Proceedings·Terry A Jacobson
Jan 25, 2011·Cardiology Clinics·Michael H Davidson
Sep 22, 2010·Atherosclerosis·Jin WiSang-Hak Lee
Sep 4, 2015·Lipids in Health and Disease·Richard L DunbarMichael H Davidson
Aug 26, 2015·Lipids in Health and Disease·Zhu-Sheng ChuKam-Ming Ko
Mar 24, 2011·Expert Opinion on Pharmacotherapy·Gissette Reyes-SofferHenry N Ginsberg
Jun 7, 2012·International Journal of Cardiology·Ramprasad GadiVincent M Figueredo
Jul 13, 2012·Atherosclerosis·John GregsonCarol Koro
Jan 25, 2012·Atherosclerosis·Sang-Hak LeeYangsoo Jang
Feb 18, 2015·Frontiers in Pharmacology·Omar Patiño-RodríguezJosé Pérez-Urizar
Mar 12, 2015·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Mar 27, 2019·Journal of Cardiovascular Pharmacology and Therapeutics·Eleni PappaMoses S Elisaf
Jun 2, 2012·Expert Review of Cardiovascular Therapy·Michel Farnier
Sep 25, 2019·Nature Reviews. Drug Discovery·Xiao ZhaoFei-Fei Liu
Feb 6, 2017·BMC Medicine·Amirhossein SahebkarUNKNOWN Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
Sep 4, 2018·Aging Medicine·Chunli WangShuyan Chen
Jan 1, 2013·Journal of Drug Assessment·Niki KatsikiAsterios Karagiannis
May 17, 2017·Therapeutic Advances in Endocrinology and Metabolism·Kiran JoglekarAmik Sodhi
Sep 15, 2020·Archives of Gerontology and Geriatrics·Adrian ZubrzyckiZbigniew Kmieć